v3.26.1
Segment Reporting - Schedule Segment Profit or Loss, Including Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Total general and administrative expenses $ 14,178   $ 7,220   $ 26,954 $ 14,675
Total operating expenses 59,951   32,018   120,191 73,806
Operating loss (59,951)   (32,018)   (120,191) (73,806)
Interest income 4,576   4,682   8,659 9,696
Total other income 4,576   4,682   8,659 9,696
Net income before losses (55,375)   (27,336)   (111,532) (64,110)
Net loss (55,436) $ (56,211) (27,388) $ (36,846) (111,647) (64,234)
Reportable Segment            
Segment Reporting [Line Items]            
Manufacturing and process development 11,484   8,266   34,277 26,921
Clinical operations and development 21,384   10,461   36,311 20,487
Research and development personnel cost and other (including stock-based compensation) 12,469   5,528   21,588 10,624
Research 436   543   1,061 1,099
Total research and development 45,773   24,798   93,237 59,131
General and administrative personnel costs (including stock-based compensation) 8,871   4,854   16,834 9,686
Professional fees 4,677   1,392   8,960 2,896
Facility costs, IT, office expense and other 630   974   1,160 2,093
Total general and administrative expenses 14,178   7,220   26,954 14,675
Total operating expenses 59,951   32,018   120,191 73,806
Operating loss (59,951)   (32,018)   (120,191) (73,806)
Interest income 4,576   4,682   8,659 9,696
Total other income 4,576   4,682   8,659 9,696
Net income before losses (55,375)   (27,336)   (111,532) (64,110)
Income tax expense (61)   (52)   (115) (124)
Net loss $ (55,436)   $ (27,388)   $ (111,647) $ (64,234)